[Federal Register Volume 69, Number 102 (Wednesday, May 26, 2004)]
[Notices]
[Pages 29978-29979]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-11818]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importation of Controlled Substances; Notice of Application

    Pursuant to section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(1)), the Attorney General shall, prior to 
issuing a registration under this Section to a

[[Page 29979]]

bulk manufacturer of a controlled substance in Schedule I or II and 
prior to issuing a registration under Section 1002(a) authorizing the 
importation of such a substance, provide manufacturers holding 
registrations for the bulk manufacture of the substance an opportunity 
for a hearing.
    Therefore, in accordance with Sec.  1301.34 of Title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on March 17, 
2004, Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, 
Petersburg, Virginia 23805, made application by renewal to the Drug 
Enforcement Administration to be registered as an importer of 
Phenylacetone (8501), a basic class of controlled substance listed in 
Schedule II.
    The firm plans to import Phenylacetone for the bulk manufacture of 
amphetamine.
    Any manufacturer holding, or applying for, registration as a bulk 
manufacturer of the basic classes of controlled substances may file 
written comments on or objections to the application described above 
and may, at the same time, file a written request for a hearing on such 
application in accordance with 21 CFR 1301.43 in such form as 
prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administrator, Office of 
Diversion Control, Drug Enforcement Administration, United States 
Department of Justice, Washington, DC 20537, Attention: Federal 
Register Representative, Office of Chief Counsel (CCD) and must be 
filed no later than June 25, 2004.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 
1301.34(b),(c),(d),(e), and (f). As noted in a previous 1975 notice at 
40 FR 43745-46 (September 23, 1975), all applicants for registration to 
import basic class of any controlled substance in Schedule I or II are 
and will continue to be required to demonstrate to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration that the requirements for such registration pursuant to 
21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 
1311.42(a),(b),(c),(d),(e), and (f) are satisfied.

    Dated: May 5, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-11818 Filed 5-25-04; 8:45 am]
BILLING CODE 4410-09-M